In recent years, SGLT2 inhibitors have emerged as effective agents for managing HF, reducing symptoms, recurrent hospitalizations and improving survival and quality of life in HFrEF patients, regardless of diabetes status [4]. The gene discussed is SLC5A2; the disease is diabetes mellitus.